Piyush K. Agarwal, M.D.
Piyush K. Agarwal, M.D.
Investigator
Head, Bladder Cancer Section

Center for Cancer Research
National Cancer Institute

Building 10 - Hatfield CRC, Room 2-5952
Bethesda, MD 20892-1210
301-496-6353

Dr. Agarwal is a tenure-track investigator and the Head of the Bladder Cancer Section in the Urologic Oncology Branch. He specializes in multidisciplinary management of urothelial cancer and complex surgical techniques including robotic cystectomy and continent urinary diversions. He is also an expert in other urologic cancers including prostate, testicular, and penile carcinoma. His clinical and laboratory research focus on all aspects of bladder cancer, specifically, Bacillus Calmette-Guerin (BCG)-refractory disease and molecular targeted therapy. He is currently evaluating the addition of a vaccine to BCG in high-grade bladder cancer in a Phase II Clinical Trial.

Areas of Expertise
1) urothelial cancer 2) bladder cancer 3) immunotherapy 4) open and robotic surgery 5) targeted therapy 6) intravesical therapy
Link to Clinicaltrials.gov Protocol ID Referral Phone

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

NCI-14-C-0036 301-435-6255

Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue

NCI-15-C-0087 301-435-6255

Dr. Agarwal is interested in targeted therapy for bladder cancer. One of his current projects include molecular targeted photoimmunotherapy in bladder cancer targeting EGFR, FGFR3, and other mutated and/or over-expressed surface receptors in urothelial cancer. This is in collaboration with Dr. Kobayashi and Dr. Choyke. In addition, he is starting a randomized phase I/II clinical trial for patients with high grade bladder cancer that have failed BCG that is looking at the efficacy of a vaccine combined with BCG. This is done in collaboration with Dr. Gulley and Dr. Schlom.

Scientific Focus Areas:
Cancer Biology, Cell Biology, Clinical Research, Genetics and Genomics, Molecular Biology and Biochemistry
Selected Recent Publications
  1. Weintraub MD, Li QQ, Agarwal PK.
    Mol Clin Oncol. 2: 656-60, 2014. [ Journal Article ]
  2. Ahmed K, Khan SA, Hayn MH, Agarwal PK, Badani KK, Balbay MD, Castle EP, Dasgupta P, Ghavamian R, Guru KA, Hemal AK, Hollenbeck BK, Kibel AS, Menon M, Mottrie A, Nepple K, Pattaras JG, Peabody JO, Poulakis V, Pruthi RS, Redorta JP, Rha KH, Richstone L, Saar M, Scherr DS, Siemer S, Stoeckle M, Wallen EM, Weizer AZ, Wiklund P, Wilson T, Woods M, Khan MS.
    Eur. Urol. 65: 340-7, 2014. [ Journal Article ]
  3. Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kevin Kelly W, Agarwal PK, Koppie TM, Kaag MG, Quinn DI, Vogelzang NJ, Sridhar SS.
    Urol. Oncol. 32: 637-44, 2014. [ Journal Article ]
  4. Park JC, Citrin DE, Agarwal PK, Apolo AB.
    Curr Probl Cancer. 38: 80-108, 2014. [ Journal Article ]
  5. Ghosh M, Brancato SJ, Agarwal PK, Apolo AB.
    Curr Opin Oncol. 26: 305-20, 2014. [ Journal Article ]

Dr. Agarwal is a tenure-track investigator and the Head of the Bladder Cancer Section in the Urologic Oncology Branch of the National Cancer Institute, National Institutes of Health in Bethesda, MD. He received his M.D. from the Cornell (Weill) University School of Medicine in New York, New York. He then completed his urology residency at Case Western Reserve University in Cleveland, Ohio. He then went on to the University of Texas MD Anderson Cancer Center where he completed a fellowship in urologic oncology. Before coming to the NIH, Dr. Agarwal was a faculty member at the Henry Ford Hospital Vattikuti Urology Institute where he served as the Director of Robotic Bladder Surgery. Dr. Agarwal is a Board Certified and fellowship trained Urologic Oncologic Surgeon. Dr. Agarwal specializes in multidisciplinary management of bladder cancer and complex surgical techniques including robotic cystectomy and continent urinary diversions. He is also an expert in other urologic cancers including prostate, testicular, and penile carcinoma. His clinical and laboratory research focus on all aspects of bladder cancer, specifically, BCG-refractory disease and molecular targeted therapy.

Name Position
Sam Joseph Brancato M.D. Clinical Fellow
Julian Custer Research Biologist (Contr)
Rebecca Dolan Nurse Practitioner (Contr.)
Sarah M. Fowler R.N. Clinical Research Nurse
Iawen Hsu Ph.D. Postdoctoral Fellow (Visiting)
Keidren Lewi Special Volunteer
Qingdi Quentin Li M.D., Ph.D. Research Biologist
Reema S. Railkar Ph.D. Postdoctoral Fellow (Visiting)
Srinivas Vourganti M.D. Special Volunteer
Yvonne Wall Patient Care Coordinator (Contr.)

Summary

Dr. Agarwal is a tenure-track investigator and the Head of the Bladder Cancer Section in the Urologic Oncology Branch. He specializes in multidisciplinary management of urothelial cancer and complex surgical techniques including robotic cystectomy and continent urinary diversions. He is also an expert in other urologic cancers including prostate, testicular, and penile carcinoma. His clinical and laboratory research focus on all aspects of bladder cancer, specifically, Bacillus Calmette-Guerin (BCG)-refractory disease and molecular targeted therapy. He is currently evaluating the addition of a vaccine to BCG in high-grade bladder cancer in a Phase II Clinical Trial.

Areas of Expertise
1) urothelial cancer 2) bladder cancer 3) immunotherapy 4) open and robotic surgery 5) targeted therapy 6) intravesical therapy

Clinical Trials

Link to Clinicaltrials.gov Protocol ID Referral Phone

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

NCI-14-C-0036 301-435-6255

Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue

NCI-15-C-0087 301-435-6255

Research

Dr. Agarwal is interested in targeted therapy for bladder cancer. One of his current projects include molecular targeted photoimmunotherapy in bladder cancer targeting EGFR, FGFR3, and other mutated and/or over-expressed surface receptors in urothelial cancer. This is in collaboration with Dr. Kobayashi and Dr. Choyke. In addition, he is starting a randomized phase I/II clinical trial for patients with high grade bladder cancer that have failed BCG that is looking at the efficacy of a vaccine combined with BCG. This is done in collaboration with Dr. Gulley and Dr. Schlom.

Scientific Focus Areas:
Cancer Biology, Cell Biology, Clinical Research, Genetics and Genomics, Molecular Biology and Biochemistry

Publications

Selected Recent Publications
  1. Weintraub MD, Li QQ, Agarwal PK.
    Mol Clin Oncol. 2: 656-60, 2014. [ Journal Article ]
  2. Ahmed K, Khan SA, Hayn MH, Agarwal PK, Badani KK, Balbay MD, Castle EP, Dasgupta P, Ghavamian R, Guru KA, Hemal AK, Hollenbeck BK, Kibel AS, Menon M, Mottrie A, Nepple K, Pattaras JG, Peabody JO, Poulakis V, Pruthi RS, Redorta JP, Rha KH, Richstone L, Saar M, Scherr DS, Siemer S, Stoeckle M, Wallen EM, Weizer AZ, Wiklund P, Wilson T, Woods M, Khan MS.
    Eur. Urol. 65: 340-7, 2014. [ Journal Article ]
  3. Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kevin Kelly W, Agarwal PK, Koppie TM, Kaag MG, Quinn DI, Vogelzang NJ, Sridhar SS.
    Urol. Oncol. 32: 637-44, 2014. [ Journal Article ]
  4. Park JC, Citrin DE, Agarwal PK, Apolo AB.
    Curr Probl Cancer. 38: 80-108, 2014. [ Journal Article ]
  5. Ghosh M, Brancato SJ, Agarwal PK, Apolo AB.
    Curr Opin Oncol. 26: 305-20, 2014. [ Journal Article ]

Biography

Dr. Agarwal is a tenure-track investigator and the Head of the Bladder Cancer Section in the Urologic Oncology Branch of the National Cancer Institute, National Institutes of Health in Bethesda, MD. He received his M.D. from the Cornell (Weill) University School of Medicine in New York, New York. He then completed his urology residency at Case Western Reserve University in Cleveland, Ohio. He then went on to the University of Texas MD Anderson Cancer Center where he completed a fellowship in urologic oncology. Before coming to the NIH, Dr. Agarwal was a faculty member at the Henry Ford Hospital Vattikuti Urology Institute where he served as the Director of Robotic Bladder Surgery. Dr. Agarwal is a Board Certified and fellowship trained Urologic Oncologic Surgeon. Dr. Agarwal specializes in multidisciplinary management of bladder cancer and complex surgical techniques including robotic cystectomy and continent urinary diversions. He is also an expert in other urologic cancers including prostate, testicular, and penile carcinoma. His clinical and laboratory research focus on all aspects of bladder cancer, specifically, BCG-refractory disease and molecular targeted therapy.

Team

Name Position
Sam Joseph Brancato M.D. Clinical Fellow
Julian Custer Research Biologist (Contr)
Rebecca Dolan Nurse Practitioner (Contr.)
Sarah M. Fowler R.N. Clinical Research Nurse
Iawen Hsu Ph.D. Postdoctoral Fellow (Visiting)
Keidren Lewi Special Volunteer
Qingdi Quentin Li M.D., Ph.D. Research Biologist
Reema S. Railkar Ph.D. Postdoctoral Fellow (Visiting)
Srinivas Vourganti M.D. Special Volunteer
Yvonne Wall Patient Care Coordinator (Contr.)